Scarica l'app Stockscreener
11.45
2.97%
-0.35
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DYN Giù?
Forum
Previsione
Precedente Chiudi:
$11.80
Aprire:
$11.8
Volume 24 ore:
1.16M
Relative Volume:
0.61
Capitalizzazione di mercato:
$1.33B
Reddito:
-
Utile/perdita netta:
$-294.51M
Rapporto P/E:
-3.2163
EPS:
-3.56
Flusso di cassa netto:
$-244.42M
1 W Prestazione:
-5.22%
1M Prestazione:
-13.06%
6M Prestazione:
-66.15%
1 anno Prestazione:
-59.67%
Intervallo 1D:
$11.24
$11.99
Intervallo di 1 settimana:
$10.72
$12.43
Portata 52W:
$10.72
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
Nome
Dyne Therapeutics Inc
Settore
Industria
Telefono
(781) 786-8230
Indirizzo
1560 TRAPELO ROAD, WALTHAM
Confronta DYN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
11.45 | 1.33B | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-10-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Reiterato | Chardan Capital Markets | Buy |
| 2024-04-30 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-20 | Iniziato | H.C. Wainwright | Buy |
| 2023-02-27 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Iniziato | Oppenheimer | Outperform |
| 2023-01-26 | Iniziato | Guggenheim | Buy |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Outperform |
| 2020-10-12 | Iniziato | JP Morgan | Overweight |
| 2020-10-12 | Iniziato | Jefferies | Buy |
| 2020-10-12 | Iniziato | Piper Sandler | Overweight |
| 2020-10-12 | Iniziato | Stifel | Buy |
Mostra tutto
Dyne Therapeutics Inc Borsa (DYN) Ultime notizie
BMO maintains Dyne Therapeutics stock with $50 target By Investing.com - Investing.com Canada
Dyne names Editas’ Erick Lucera CFO - BioCentury
JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path - Benzinga India
Sector Update: Health Care Stocks Steady Premarket Friday -March 21, 2025 at 09:24 am EDT - Marketscreener.com
JPMorgan cuts Dyne Therapeutics stock target to $17 from $18 By Investing.com - Investing.com Canada
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer - The National Law Review
Dyne Therapeutics names new CFO ahead of clinical milestones By Investing.com - Investing.com South Africa
Dyne Therapeutics Names Erick Lucera as CFO -March 20, 2025 at 05:36 pm EDT - Marketscreener.com
Dyne Therapeutics Appoints Erick Lucera as CFO - TipRanks
Dyne Therapeutics Announces Appointment of Erick J. Lucera As Chief Financial Officer - Marketscreener.com
Dyne Therapeutics names new CFO ahead of clinical milestones - Investing.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq - GlobeNewswire
New Dyne Therapeutics CFO Secures Major Equity Package Worth 280,600 Shares - StockTitan
Dyne Therapeutics Strengthens Commercial Launch Plans With Strategic CFO Appointment - StockTitan
(DYN) Technical Data - Stock Traders Daily
Dyne reports new long-term data from Phase 1/2 DELIVER trial of DYNE-251 - MSN
Stifel maintains Buy on Dyne Therapeutics with $66 target By Investing.com - Investing.com Canada
H.C. Wainwright maintains $46 target on Dyne Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains $46 target on Dyne Therapeutics stock - Investing.com
Dyne Therapeutics Says Trial of Potential Duchenne Muscular Dystrophy Drug Shows 'Meaningful' Results - Marketscreener.com
Dyne’s Duchenne Exon Skipping Oligomer Shows ‘Differentiated’ Clinical Effect - BioSpace
Dyne Therapeutics Announces New Long-Term Clinical Data - GlobeNewswire
Dyne : Phase 1/2 Trial Of DYNE-251 In DMD Shows Sustained Functional Improvements Through 18 Months - Nasdaq
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months - The Manila Times
Dyne Therapeutics Reports Promising Long-Term Data for DYNE-251 in Duchenne Muscular Dystrophy with Plans for Accelerated Approval Submission - Nasdaq
Game-Changing DMD Clinical Trial: Dyne's DYNE-251 Achieves 8.72% Dystrophin Expression - StockTitan
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Buy” by Brokerages - Defense World
Dyne wins new Outperform at BMO on prospects for lead drug - MSN
BMO Capital Markets Begins Coverage on Dyne Therapeutics (NASDAQ:DYN) - Defense World
Dyne therapeutics chief commercial officer sells $1,733 in stock By Investing.com - Investing.com Australia
Dyne therapeutics chief commercial officer sells $1,733 in stock - Investing.com
Dyne Therapeutics chief scientific officer sells shares worth $24,501 By Investing.com - Investing.com South Africa
Dyne Therapeutics chief scientific officer sells shares worth $24,501 - Investing.com India
GDX Is Looking To Retest 2020 Highs; Gold To 3K Soon? - The Globe and Mail
Dyne: Accelerated Approval DYNE-101 Might Be Possible With Surrogate Biomarker (DYN) - Seeking Alpha
BMO Capital Initiates Coverage of Dyne Therapeutics (DYN) with Outperform Recommendation - MSN
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks - Yahoo Finance
BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating - Yahoo Finance
BMO Capital Initiates Dyne Therapeutics Inc at Outperform With $50 Price Target -March 12, 2025 at 07:22 am EDT - Marketscreener.com
Dyne Therapeutics: Innovative Approaches and Promising Clinical Programs Drive Buy Rating - TipRanks
Dyne Therapeutics initiated with an Outperform at BMO Capital - TipRanks
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum - GlobeNewswire
Neuromuscular Disease Breakthroughs: Dyne Therapeutics Reveals Latest Progress at CNS Forum - StockTitan
Dyne Therapeutics (NASDAQ:DYN) Research Coverage Started at Scotiabank - Defense World
Critical Analysis: Dyne Therapeutics (NASDAQ:DYN) and Lantern Pharma (NASDAQ:LTRN) - Defense World
Trend Tracker for (DYN) - Stock Traders Daily
Dyne Therapeutics (NASDAQ:DYN) Now Covered by Analysts at Scotiabank - MarketBeat
Scotiabank Initiates Coverage of Dyne Therapeutics (DYN) with Sector Outperform Recommendation - Nasdaq
Dyne Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Thinking Of Investing In Dyne Therapeutics Inc (NASDAQ: DYN) Stock? Read This First - Stocks Register
Scotiabank sets Dyne Therapeutics stock target at $50, cites entry point - Investing.com India
Dyne Therapeutics Inc Azioni (DYN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Dyne Therapeutics Inc Azioni (DYN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Scalzo Richard William | SVP, Head of Finance & Admin. |
Mar 11 '25 |
Sale |
11.38 |
1,343 |
15,283 |
122,330 |
| Beskrovnaya Oxana | Chief Scientific Officer |
Mar 11 '25 |
Sale |
11.38 |
2,153 |
24,501 |
195,840 |
0.39%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):